IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 171 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $129 | -99.9% | 20,200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $193,000 | -29.6% | 20,200 | -18.9% | 0.00% | 0.0% |
| Q2 2022 | $274,000 | -89.4% | 24,900 | -76.3% | 0.00% | -90.0% |
| Q3 2021 | $2,589,000 | -35.8% | 105,000 | -32.3% | 0.01% | -33.3% |
| Q2 2021 | $4,033,000 | -17.8% | 155,000 | 0.0% | 0.02% | -16.7% |
| Q1 2021 | $4,907,000 | +622.7% | 155,000 | +958.2% | 0.02% | +500.0% |
| Q4 2020 | $679,000 | +23.2% | 14,647 | -12.5% | 0.00% | +50.0% |
| Q3 2020 | $551,000 | +6.2% | 16,743 | -11.5% | 0.00% | 0.0% |
| Q2 2020 | $519,000 | -86.9% | 18,911 | -85.7% | 0.00% | -90.5% |
| Q1 2020 | $3,957,000 | +8.8% | 132,200 | +0.6% | 0.02% | +40.0% |
| Q4 2019 | $3,637,000 | -21.8% | 131,400 | -48.6% | 0.02% | +50.0% |
| Q3 2019 | $4,650,000 | +49.5% | 255,600 | +101.4% | 0.01% | -28.6% |
| Q2 2019 | $3,111,000 | +172.7% | 126,900 | +5.8% | 0.01% | +180.0% |
| Q1 2019 | $1,141,000 | – | 120,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MHR Fund Management | 11,997,103 | $84,459,605 | 11.88% |
| MPM BioImpact LLC | 2,950,118 | $20,768,831 | 4.18% |
| Perceptive Advisors | 14,036,410 | $98,816,326 | 2.86% |
| Velan Capital Investment Management LP | 240,000 | $1,689,600 | 1.57% |
| Parametrica Management Ltd | 96,500 | $679,360 | 1.31% |
| Boxer Capital, LLC | 3,705,133 | $26,084 | 1.21% |
| Soleus Capital Management, L.P. | 1,239,777 | $8,728,030 | 0.97% |
| Opaleye Management Inc. | 421,000 | $2,963,840 | 0.71% |
| 683 Capital Management, LLC | 1,400,000 | $9,856,000 | 0.71% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,758,759 | $12,381,665 | 0.70% |